Zhifei Biological Products (300122.SZ)

Executive Summary

Zhifei Biological Products is a leading Chinese biopharmaceutical company specializing in the research, development, and distribution of vaccines and biologics. Founded in 2003 and headquartered in Hefei, the company has grown to become one of China's largest vaccine manufacturers, with a strong domestic distribution network and robust R&D capabilities. Its diverse portfolio includes recombinant vaccines for COVID-19 (ZF2001), hepatitis B, and other infectious diseases, as well as a partnership to distribute Merck's Gardasil HPV vaccine in China. With a market capitalization of approximately $4.4 billion, Zhifei benefits from China's expanding vaccination programs and increasing demand for preventive healthcare. The company's strategic focus on innovative biologics and international partnerships positions it for continued growth, though it faces competitive pressures and regulatory risks.

Upcoming Catalysts (preview)

• Q4 2026Potential FDA or WHO approval for ZF2001 COVID-19 vaccine booster60% success
• Q1 2027Launch of self-developed 9-valent HPV vaccine candidate50% success
• Q3 2026Expansion of international distribution partnerships for existing vaccines75% success